It has been shown that activation of IGFBP-3R by IGFBP-3 and IGFBP-3R agonistic mAb inhibits cell growth by inducing apoptosis and by tumor-induced NF-κB activity specifically in cancer cells, but not in normal cells. Here, TMEM219 is linked to neoplasm.